Fennec Pharma up as FDA accepts resubmitted application for hearing loss drug

Fennec Pharmaceuticals

27/04/2022 12:58

** Shares of drug developer  FENC.O  rise 2.2% to $6.40
premarket
    ** Co says U.S. FDA has accepted its resubmitted marketing
application for treatment for preventing chemotherapy-induced
hearing loss in pediatric patients (https://refini.tv/3MyZvZv)
    ** Agency has declined to approve the drug PEDMARK twice,
citing manufacturing deficiencies  urn:newsml:reuters.com:*:nL4N2SL306
    ** Target date set for September 23
    ** Stock up 42.3% this year, as of last close

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))